微生物学免疫学进展
微生物學免疫學進展
미생물학면역학진전
PROGRESS IN MICROBIOLOGY AND IMMUNOLOGY
2014年
1期
17-19
,共3页
李娟%李红%崔晓雨%赵慧%李长贵
李娟%李紅%崔曉雨%趙慧%李長貴
리연%리홍%최효우%조혜%리장귀
人乳头瘤病毒%疫苗%比对研究
人乳頭瘤病毒%疫苗%比對研究
인유두류병독%역묘%비대연구
Human papillomavirus%Vaccine%Investigation
目的:为保证人乳头瘤病毒疫苗临床血清抗体检测的准确性和有效性,对ELISA检测方法进行了比对研究。方法采用编盲的200对血清,分别在两个不同实验室使用ELISA法进行HPV16、HPV18型抗体检测,并对结果进行统计学分析。结果两个实验室对免前、免后血清的16、18型抗体检测结果,阴阳性符合率均大于93%,统计学分析显示两个实验室的检测结果差异无统计学意义。免后血清HPV16型抗体几何平均效价比值为1.10, HPV18型比值为1.17,均在预先设定的范围内。结论该方法在两个不同实验室的检测结果一致性良好,可用于HPV疫苗临床血清学样本的检测。
目的:為保證人乳頭瘤病毒疫苗臨床血清抗體檢測的準確性和有效性,對ELISA檢測方法進行瞭比對研究。方法採用編盲的200對血清,分彆在兩箇不同實驗室使用ELISA法進行HPV16、HPV18型抗體檢測,併對結果進行統計學分析。結果兩箇實驗室對免前、免後血清的16、18型抗體檢測結果,陰暘性符閤率均大于93%,統計學分析顯示兩箇實驗室的檢測結果差異無統計學意義。免後血清HPV16型抗體幾何平均效價比值為1.10, HPV18型比值為1.17,均在預先設定的範圍內。結論該方法在兩箇不同實驗室的檢測結果一緻性良好,可用于HPV疫苗臨床血清學樣本的檢測。
목적:위보증인유두류병독역묘림상혈청항체검측적준학성화유효성,대ELISA검측방법진행료비대연구。방법채용편맹적200대혈청,분별재량개불동실험실사용ELISA법진행HPV16、HPV18형항체검측,병대결과진행통계학분석。결과량개실험실대면전、면후혈청적16、18형항체검측결과,음양성부합솔균대우93%,통계학분석현시량개실험실적검측결과차이무통계학의의。면후혈청HPV16형항체궤하평균효개비치위1.10, HPV18형비치위1.17,균재예선설정적범위내。결론해방법재량개불동실험실적검측결과일치성량호,가용우HPV역묘림상혈청학양본적검측。
Objective To ensure the investigation for accurance and efficency of measurement HPV-16 and HPV-18 antibodies in different laboratories , so as to support the application of this method for clinical samples evaluation . Methods The study was performed in detection of HPV-16 and HPV-18 antibody titers by testing the panel of 200 paired samples ( pre-and post-vaccination ) both at NIFDC and Rixensart .Results The agreement of negative and positive concordance at both laboratories is ≥90%.There is no significant difference proved by Bartlett ’ s and Levene ’ s statistic tests.The GMC ratio of post-vaccination samples between two laboratories is 1.10 and 1.17 for HPV-16 and HPV-18 type, respectively.The overall comparative data between both laboratories are very good and meet the acceptance criteria . Conclusion The results showed that the acceptance criteria are fully met at two laboratories and the antibodies testing method could be used in detection of samples from clinical trials .